My watch list
my.bionity.com  
Login  

Acridine carboxamide



Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

Additional recommended knowledge

While the agent was well-tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

References

  1. ^ Dittrich C, Dieras V, Kerbrat P, et al (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs 21 (3): 347-52. PMID 14578683.
  2. ^ Caponigro F, Dittrich C, Sorensen JB, et al (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer 38 (1): 70-4. PMID 11750842.
  3. ^ Twelves C, Campone M, Coudert B, et al (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777-80. PMID 12075748.
  4. ^ Dittrich C, Coudert B, Paz-Ares L, et al (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer 39 (3): 330-4. PMID 12565985.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Acridine_carboxamide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE